Concomitant administration of IXIARO with inactivated hepatitis A vaccine has been evaluated in one clinical study. There was no interference with the immune response to Japanese encephalitis virus (JEV) and hepatitis A virus (HAV) vaccines, respectively. Concomitant administration of IXIARO and hepatitis A vaccine was shown to be non-inferior to single vaccinations with regard to geometric mean titres (GMT) of anti-JEV neutralizing antibody and HAV antibody, and for seroconversion rates (see Pharmacology: Pharmacodynamics under Actions).
There were no statistically significant higher rates in systemic or injection site adverse reactions among subjects who received concomitant vaccination with Ixiaro and HAV compared with those who received Ixiaro or HAV alone.
It is recommended to use the contralateral site if IXIARO is co-administered with another vaccine.
In patients receiving immunosuppressive therapy or patients with immunodeficiency an adequate immune response may not be obtained.
Paediatric population: No interaction studies have been performed in children and adolescents.